openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
Warnings Neostigmine Methylsulfate Injection, USP should be used with caution in patients with epilepsy, bronchial asthma, bradycardia, recent coronary occlusion, vagotonia, hyperthyroidism, cardiac arrhythmias or peptic ulcer. When large doses of Neostigmine are administered, the prior or simultaneous injection of Atropine Sulfate may be advisable. Separate syringes should be used for the Neostigmine and Atropine. Because of the possibility of hypersensitivity in an occasional patient, Atropine and anti-shock medication should always be readily available.
Adverse Reactions Side effects are generally due to an exaggeration of pharmacological effects of which salivation and fasciculation are the most common. Bowel cramps and diarrhea may also occur. The following additional adverse reactions have been reported following the use of either Neostigmine Bromide or Neostigmine Methylsulfate. Allergic : Allergic reactions and anaphylaxis. Neurologic : Dizziness, convulsions, loss of consciousness, drowsiness, headache, dysarthria, miosis and visual changes. Cardiovascular: Cardiac arrhythmias (including bradycardia, tachycardia, A-V block and nodal rhythm) and nonspecific EKG changes have been reported, as well as cardiac arrest, syncope and hypotension. These have been predominantly noted following the use of the injectable form of Neostigmine Methylsulfate. Respiratory : Increased oral, pharyngeal and bronchial secretions, dyspnea, respiratory depression, respiratory arrest and bronchospasm. Dermatologic: Rash and urticaria. Gastrointestinal : Nausea, emesis, flatulence and increased peristalsis. Genitourinary : Urinary frequency. Musculoskeletal: Muscle cramps and spasms, arthralgia. Miscellaneous : Diaphoresis, flushing and weakness.